Orphan Drugs As Hot Properties...

...If you know how to squeeze the system, and the right participants, at the right places. There's profit potential for you, and boy aren't they just making the most of it.

When the Patient Is a Gold Mine: The Trouble With Rare-Disease Drugs

With a flagship treatment that helps fewer than 11,000 people, how is Alexion making so much money?

by 

Benjamin Elgin

, 

Doni Bloomfield

, and 

Caroline Chen

May 24, 2017, 1:00 AM PDT